SEC Form 4 · accession 0000899243-18-008156

Global Blood Therapeutics, Inc. · GBT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Jung Choi

Officer — See Remarks

Period of report

Mar 16, 2018

Accepted (ET)

Mar 20, 2018 · 5:30 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001629137

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F2	Mar 16, 2018	S	1,600	$54.15	D	139,277	D
Common Stock	Mar 16, 2018	M	198	$3.40	A	139,475	D
Common Stock	Mar 16, 2018	M	601	$3.40	A	140,076	D
Common Stock	Mar 16, 2018	M	601	$3.40	A	140,677	D
Common Stock	Mar 16, 2018	S	1,400	$54.15	D	139,277	D
Common Stock	holding	—	—		—	25,000	I	By Trust

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F3	$3.40	Mar 16, 2018	M	198	D	—	Apr 8, 2025	Common Stock	198	75,360	D
Stock Option (Right to Buy)^F4	$3.40	Mar 16, 2018	M	601	D	—	Apr 8, 2025	Common Stock	601	3,877	D
Stock Option (Right to Buy)^F5	$3.40	Mar 16, 2018	M	601	D	—	Apr 8, 2025	Common Stock	601	3,877	D

Explanation of responses

F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2These shares of Common Stock were subject to the Issuer's right of repurchase, which lapsed with respect to 25% of the shares on April 6, 2016 and in 12 equal quarterly installments thereafter.
F325% of the shares subject to this option vested and became exercisable on April 6, 2016 and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter.
F4On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On March 10, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option.
F5On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On September 29, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option.

Remarks

Chief Business and Strategy Officer